Skip to main content

Table 1 Total number of samples successfully amplified for pfmdr1 copy number and sequenced for pfmdr1 and pfk13 from therapeutic efficacy monitoring in Angola, 2015

From: Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015

 

Benguela

Lunda Sul

Zaire

Total

Pretreatment

 pfk13 sequence

188/188 (100%)

82/82 (100%)

199/199 (100%)

469/469 (100%)

 pfmdr1 copy number

195/199 (98%)

99/101 (98%)

203/206 (99%)

497/506 (98%)

 pfmdr1 sequence

194/198 (97%)

96/101 (95%)

201/207 (97%)

491/506 (96%)

Day of late treatment failure

 pfk13 sequence

15/15 (100%)

0

35/35 (100%)

50/50 (100%)

 pfmdr1 copy number

15/15 (100%)

0

31/34 (91%)

46/49 (94%)

 pfmdr1 sequence

15/15 (100%)

0

35/35 (100%)

50/50 (100%)

Total samples

 pfk13 sequence

203/203 (100%)

82/82 (100%)

234/234 (100%)

519/519 (100%)

 pfmdr1 copy number

210/214 (98%)

99/101 (98%)

234/240 (98%)

543/555 (98%)

 pfmdr1 sequence

209/213 (97%)

96/101 (95%)

236/242 (97%)

541/556 (97%)